ClinicalTrials.gg
Not yet recruitingNCT07946887INT-REDS-ASDUpdated Nov 18, 2026

Interoception in Adolescents With Restrictive Eating Disorders and Autism Spectrum Disorder

An observational study in Anorexia Nervosa, Avoidant / Restrictive Food Intake Disorder and Autism Spectrum Disorder, sponsored by Fondazione IRCCS San Gerardo dei Tintori. Not yet recruiting at 4 sites in Italy. Open to participants aged 13 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Fondazione IRCCS San Gerardo dei Tintori · Observational

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
180
Ages
13 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 31 studies in Anorexia Nervosa with a site in Italy — 11 open to participants now, 12 under way, none of them phase 3. Anorexia Nervosa · Italy.

Planned enrollment
2nd of 19
180 · median 60
Started
2026
with 1 other
Observational
19 of 31
5 open now
Primary completion
2027-11
later than 10 of 11 live
Registered
31st of 31
by date
Lead sponsor
1 of 31
Fondazione IRCCS San Gerardo dei Tintori

Among the 31 studies in Anorexia Nervosa with a site in Italy, this one is the 2nd largest by planned enrollment of the 19 observational ones that give a count, is one of 2 that started in 2026, is one of 19 observational ones, reaches primary completion later than 10 of the 11 other live ones, and was the 31st registered.

Anorexia Nervosa

471 studies on the registry are indexed under Anorexia Nervosa; 128 are open to participants now.

Browse Anorexia Nervosa studies →

Open to participants now

11 of the 31 studies in Anorexia Nervosa with a site in Italy are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 82 Anorexia Nervosa studies recruiting now, 18 (22%) set no upper age limit and 60 (73%) stop at 75 or younger; 48 take children under 18; 26 take healthy volunteers.

This study: 13 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Anorexia Nervosa with a site in Italy, or all of them as a file.
02

Study summary

The goal of this observational study is to describe interoception (the ability to sense signals from inside the body, such as heartbeat, hunger, and fullness) in three groups of adolescents aged 13 to 18: those with restrictive eating disorders (REDs), those with autism spectrum disorder (ASD), and those with both REDs and ASD.

The main questions it aims to answer are:

  • What is the level of interoceptive accuracy (how precisely participants perceive their own heartbeat), as measured by the Heartbeat Counting Task (HCT), in each of the three groups?
  • What is the level of interoceptive sensitivity (how participants self-report their awareness of body signals), as measured by the Multidimensional Assessment of Interoceptive Awareness, Version 2 (MAIA-2), in each of the three groups?

In each group, researchers will also explore whether interoceptive accuracy and sensitivity are associated with:

  • socio-demographic and clinical characteristics (gender, age, body mass index, illness duration, and IQ)
  • psychological characteristics, including alexithymia (difficulty identifying and describing emotions), eating disorder symptoms and their severity, general psychological distress, and emotion dysregulation

Participants will:

  • Complete the Heartbeat Counting Task (HCT), in which they silently count their own heartbeats
  • Fill in the MAIA-2 questionnaire about body awareness, along with other questionnaires about eating behaviors, emotions, and general well-being

All information will be collected during the standard clinical assessment, with no extra visits or procedures.

Read the detailed description

Restrictive eating disorders (REDs), including anorexia nervosa and avoidant/restrictive food intake disorder, and autism spectrum disorder (ASD) frequently co-occur, and their overlap is associated with more severe psychopathology. Interoception, the process by which the nervous system senses, interprets, and integrates signals from inside the body, has been found to be impaired in both conditions, but little is known about interoception in adolescents with REDs and comorbid ASD.

Following the multidimensional model proposed by Garfinkel et al. (2015), this multicenter prospective observational study will assess two dimensions of interoception: interoceptive accuracy (objective performance in detecting internal body signals) and interoceptive sensitivity (self-reported perception of body signals). Three clinical groups of adolescents will be described: REDs only, ASD only, and REDs with comorbid ASD.

No study-specific procedures are planned. During the standard psychodiagnostic assessment, participants complete a modified Heartbeat Counting Task (HCT) with a time estimation control task, the MAIA-2, and other self-report questionnaires (TAS-20, EDI-3, SCL-90-R, AQ, EQ, DERS-IT-SF), and undergo cognitive assessment (WISC-V). Socio-demographic and clinical data are also collected. Interoceptive accuracy and sensitivity will be described in each group with measures of location and variability and 95% confidence intervals, and their associations with socio-demographic, clinical, and psychological variables will be explored.

03

Conditions studied

  • Anorexia Nervosa
  • Avoidant / Restrictive Food Intake Disorder
  • Autism Spectrum Disorder

Keywords

  • Interoception
  • Adolescent
  • restrictive eating disorder
  • Interoceptive Sensitivity
  • Heartbeat Counting Task
  • Alexithymia
  • interoceptive accuracy
04

Who can participate

Ages eligible
13 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adolescents aged 13 to 18 years with a confirmed DSM-5-TR diagnosis of restrictive eating disorder (anorexia nervosa or avoidant/restrictive food intake disorder), autism spectrum disorder (level 1), or restrictive eating disorder with comorbid autism spectrum disorder (level 1), recruited during their standard psychodiagnostic assessment among patients under the care of four Italian child and adolescent neuropsychiatry centers: Fondazione IRCCS San Gerardo dei Tintori (Monza, coordinating center), IRCCS Istituto delle Scienze Neurologiche di Bologna, Azienda Ospedale-Università Padova, and Fondazione IRCCS Mondino (Pavia).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis, according to criteria, of one of the following: restrictive eating disorder (anorexia nervosa or avoidant/restrictive food intake disorder); autism spectrum disorder, level 1; or restrictive eating disorder with comorbid autism spectrum disorder, level 1
  • Age between 13 and 18 years at diagnosis
  • Written freely given and obtained before the start of the study from the participant and/or parent or legal guardian

Exclusion criteria

Exclusion Criteria:

  • Intellectual disability (IQ \< 70)
  • Insufficient understanding of the Italian language
  • Past or current psychotic disorders
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
180 participants (estimated)
Patient registry
No

Groups and cohorts

  • Restrictive Eating Disorders (REDs)

    Adolescents aged 13 to 18 years at diagnosis with a confirmed diagnosis of a restrictive eating disorder (anorexia nervosa or avoidant/restrictive food intake disorder) according to DSM-5-TR criteria, without autism spectrum disorder.

  • Autism Spectrum Disorder (ASD)

    Adolescents aged 13 to 18 years at diagnosis with a confirmed diagnosis of autism spectrum disorder, level 1, according to DSM-5-TR criteria, without a restrictive eating disorder.

  • REDs With Comorbid ASD

    Adolescents aged 13 to 18 years at diagnosis with a confirmed diagnosis of a restrictive eating disorder (anorexia nervosa or avoidant/restrictive food intake disorder) and comorbid autism spectrum disorder, level 1, according to DSM-5-TR criteria.

06

What researchers measure

Primary outcomes

  1. Interoceptive Accuracy Measured by the Heartbeat Counting Task (HCT)

    Interoceptive accuracy assessed with a modified version of the Heartbeat Counting Task. Participants silently count their heartbeats, without taking their pulse, during four randomized time intervals while heart rate is recorded with a finger pulse oximeter. The accuracy score is calculated as the mean across intervals of \[1 - \|(recorded heartbeats - counted heartbeats) / recorded heartbeats\|\] × 100. Scores range from 0 to 100, with higher scores indicating greater interoceptive accuracy.

    Time frame: At enrollment, during the standard diagnostic assessment

  2. Interoceptive Sensibility Measured by the Multidimensional Assessment of Interoceptive Awareness, Version 2 (MAIA-2)

    Self-reported interoceptive sensibility assessed with the MAIA-2, a 37-item questionnaire rated on a 6-point scale (0-5). Mean scores are calculated for each of the 8 subscales (Noticing, Not-Distracting, Not-Worrying, Attention Regulation, Emotional Awareness, Self-Regulation, Body Listening, Trusting) and range from 0 to 5. Higher scores indicate greater interoceptive sensibility.

    Time frame: At enrollment, during the standard diagnostic assessment

Secondary outcomes

  1. Correlations Between Interoceptive Measures and Sociodemographic Variables

    Correlations of HCT accuracy (score 0-100) and MAIA-2 subscale scores (0-5) with gender (number of participants per category) and age (years), collected from clinical records. Analyzed in each clinical group.

    Time frame: At enrollment, during the standard diagnostic assessment

  2. Correlations Between Interoceptive Measures and Clinical Variables

    Correlations of HCT accuracy (score 0-100) and MAIA-2 subscale scores (0-5) with body mass index (BMI, kg/m²), duration of illness (months), and Full Scale IQ measured by the WISC-V (standard score, mean 100, SD 15), collected from clinical records. Analyzed in each clinical group.

    Time frame: At enrollment, during the standard diagnostic assessment

  3. Alexithymia Measured by the Toronto Alexithymia Scale (TAS-20)

    Alexithymia assessed with the TAS-20, a 20-item self-report questionnaire rated on a 5-point Likert scale. Total score ranges from 20 to 100 (subscales: Difficulty Identifying Feelings, Difficulty Describing Feelings, Externally Oriented Thinking); higher scores indicate greater alexithymia. Scores will be analyzed for their correlations with HCT accuracy and MAIA-2 scores in each clinical group.

    Time frame: At enrollment, during the standard diagnostic assessment

  4. Eating Disorder Symptom Severity Measured by the Eating Disorder Inventory-3 (EDI-3)

    Eating disorder symptoms assessed with the EDI-3, a 91-item self-report questionnaire comprising 12 primary scales and 6 composite scales, including the Eating Disorder Risk Composite. Raw scores are converted to T-scores; higher scores indicate greater symptom severity. Scores will be analyzed for their correlations with HCT accuracy and MAIA-2 scores in each clinical group.

    Time frame: At enrollment, during the standard diagnostic assessment

  5. General Psychopathology Measured by the Symptom Checklist-90-Revised (SCL-90-R)

    General psychopathology assessed with the SCL-90-R, a 90-item self-report questionnaire rated from 0 to 4, covering 9 symptom dimensions. The Global Severity Index (GSI) ranges from 0 to 4; higher scores indicate greater psychological distress. Scores will be analyzed for their correlations with HCT accuracy and MAIA-2 scores in each clinical group.

    Time frame: At enrollment, during the standard diagnostic assessment

  6. Emotion Dysregulation Measured by the Difficulties in Emotion Regulation Scale - Italian Short Form (DERS-IT-SF)

    Emotion dysregulation assessed with the DERS-IT-SF, a self-report questionnaire rated on a 5-point Likert scale. Higher total and subscale scores indicate greater difficulties in emotion regulation. Scores will be analyzed for their correlations with HCT accuracy and MAIA-2 scores in each clinical group.

    Time frame: At enrollment, during the standard diagnostic assessment

07

Study locations

4 sites
08

References and documents

Individual participant data

Plan to share: Undecided — A decision on sharing individual participant data has not yet been made. Any future sharing of pseudonymized data would take place only in accordance with the informed consent, the EU General Data Protection Regulation (GDPR), and applicable Italian data protection law.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.

Of 56 non-industry observational studies under Anorexia Nervosa, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 72. This study's planned 12 months is below that.

Counting every sponsor, half of 56 studies reached it within 38 months; a quarter within 16 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2026
First posted
Nov 18, 2026
StartEst.
Nov 2026
Primary completionEst.
Nov 2027
CompletionEst.
Dec 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07946887
Lead sponsor
Fondazione IRCCS San Gerardo dei Tintori
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Nov 2026 (estimated)
Primary completion
Nov 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Anna Riva, MD
Contact
anna.riva@irccs-sangerardo.it
+39 039 2333579
Gabriele Arienti, MD
Contact
gabriele.arienti@irccs-sangerardo.it
+39 039 2333579
Renata Nacinovich
study chair · Fondazione IRCCS San Gerardo dei Tintori

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion